HBIO
Harvard Bioscience Delivers Strong Q2 Performance, Raises Full Year Revenue Outlook
HARVARD BIOSCIENCE DELIVERS STRONG Q2 PERFORMANCE, RAISES FULL YEAR REVENUE OUTLOOK The Harvard Bioscience second quarter 2026 earnings conference call revealed a stellar performance for the company, highlighted by double-digit revenue growth across its CMT and preclinical portfolios. The company's disciplined focus on strategy, commercial alignment, and operational